A mutation in the JH2 pseudokinase domain of the Janus kinase 2 gene (JAK2 V617F) has been described in chronic myeloproliferative disorders (MPD). We screened 79 acute myeloid leukemia (AML) cell lines and found five positive for JAK2 V617F (HEL, MB-02, MUTZ-8, SET-2, UKE-1), 4/5 with histories of MPD/MDS. While SET-2 expressed both mutant (mu) and wild-type (wt) JAK2, remaining positives carried homo-/hemizygous JAK2 mutations. Microsatellite analysis confirmed losses of heterozygosity (LOH) affecting the JAK2 region on chromosome 9p in MB-02, MUTZ-8 and UKE-1, but also in HEL, the only JAK2mu cell line lacking any reported MPD/MDS history. All five JAK2mu cell lines displayed cytogenetic hallmarks of MDS, namely losses of 5q or 7q, remarkably in 4/5 cases affecting both chromosomes. Our combined FISH and microsatellite analysis uncovered a novel mechanism to supplement mitotic recombination previously proposed to explain JAK2 LOH, namely chromosome deletion with/without selective JAK2mu amplification. Confirming the importance of the mutated JAK2 protein for growth and prevention of apoptosis, JAK2mu cell lines displayed higher sensitivities to JAK2 inhibition than JAK2wt cell lines. In summary, JAK2 V617F cell lines, derived from patients with history of MPD/MDS, represent novel research tools for elucidating the pathobiology of this JAK2 mutation.
Introduction
An activating point mutation in the JH2 domain of Janus kinase 2 (JAK2) was recently described in chronic myeloproliferative disorders (MPD). The JAK2 V617F mutation occurs frequently in polycythemia vera (PV) (65-97% of reported cases), essential thrombocythemia (ET) (23-57%) and idiopathic myelofibrosis (IM) (35-95%). [1] [2] [3] [4] [5] [6] In isolated cases, it occurs in Philadelphianegative, but not in Philadelphia-positive chronic myeloid leukemia (CML). 6 At low percentages, the JAK2 V617F mutation has also been found in 'atypical MPD-like' chronic myelomonocytic leukemia (CMML), systemic mastocytosis (SM) and chronic neutrophilic leukemia (CNL), and also in myelodysplastic syndromes (MDS) and acute megakaryocytic leukemia (AML M7), but not in other forms of acute myeloid leukemia (AML M1-M6) or in acute lymphoblastic leukemias (ALL). [6] [7] [8] JAK2 is involved in cellular growth factor signalling, and deregulation of JAK2 by chromosomal aberrations may contribute to leukemogenesis. [9] [10] [11] [12] The mechanism whereby JAK2 V617F mutation effects protein activation, which in turn interferes with wild-type (wt) JAK2 function remains to be clarified. Continuous cell lines are useful tools for the analysis of basic aspects of normal and malignant cell biology. Therefore, we set out to screen a panel of leukemia cell lines for expression of the JAK2 V617F mutation.
Five of 79 cell lines tested JAK2 V617F positive. Cell lines MB-02, MUTZ-8, SET-2 and UKE-1 were established from AML patients with histories of MPD or MDS (42 cell lines tested), while cell line HEL was the only testing positive for JAK2 V617F of 37 leukemia cell lines without a reported history of MPD or MDS. Sequencing and site-specific restriction analysis showed that cell line SET-2 expressed both wt and the mutant JAK2, while the other cell lines expressed mutated JAK2 only. Classic cytogenetic analysis, fluorescence in situ hybridization (FISH) and microsatellite mapping were performed to investigate whether loss of heterozygosity at chromosome 9p (9pLOH) was the result of mitotic recombination as previously reported.
1,2,4
JAK2mu cell lines were more sensitive to JAK inhibition than JAK2wt cell lines. The JAK2 V617F positive cell lines may help to elucidate whether and how JAK2mu participates in the rise of these diseases.
Materials and methods

Human cell lines
The continuous cell lines were either taken from the stock of the cell bank (DSMZ -German Collection of Microorganisms and Cell Cultures) 13 or were generously provided by the original investigators. The cell lines were cultivated according to the protocols described previously. 13, 14 The following cell lines (in alphabetical order) were tested for JAK2 V617F mutation: 380 (derived from patient with B-cell precursor ALL, BCP ALL), Mutational analysis for detection of JAK2 V617F mutation JAK2 mutations were identified using the amplification-refractory mutation system (ARMS). 5 This assay uses four primers specifically to detect the mutant (279 bp) and wt (229 bp) versions of the gene plus a positive control band (463 bp). Polymerase chain reaction (PCR) primers were: forward outer
0 . Unless stated otherwise, all primers used in this study were purchased from MWG Biotech (Ebersberg, Germany). Genomic PCR amplification was performed with a DNA thermal cycler (Perkin-Elmer Cetus, Heidelberg, Germany) under the following conditions: 30 s at 941C for denaturation, 30 s at 581C for annealing and 2 min at 721C for extension. In the first of 36 cycles, HotStart Taq polymerase (Qiagen, Hilden, Germany) was activated for 15 min at 951C.
To verify the JAK2 1849G4T mutation, the 463 bp products from PCR with outer primers FO and RO were sequenced (MWG Biotech).
Additionally to confirm the JAK2 wt or mutant status and to distinguish between homozygous or heterozygous mutations, JAK2 463 bp PCR products were treated with BsaXI (New England Biolabs, Frankfurt, Germany). The BsaXI site in the wt version of JAK2 is removed by the G4T transition. 1 
Cytogenetic analysis
Karyotypic analysis and FISH were performed as described previously. 15 Tilepath bacterial artificial chromosome (BAC) clones were sourced from BAC-PAC Resources (Children's Hospital, Oakland, CA, USA), and chromosome painting probes from Cambio (Cambridge, UK). Probe preparation and labelling were as described previously. 15 Imaging and analysis were performed using an Axioscope 2 fluorescence microscope system (Zeiss, Goettingen, Germany) and Smart Capture 2 software (Applied Imaging, Newcastle, UK).
Microsatellite analysis
To verify whether JAK2 V617F mutations were paralleled by LOH at chromosome 9p, we tested six microsatellite markers for heterozygosity. 4 The size of the PCR products was verified by capillary gel electrophoresis (CEQ 8000, Beckmann Coulter, Krefeld, Germany) as previously described. 16 Asterisks indicate positive labelling for the fluorescent dye D4. Labelled oligonucleotides were obtained from Proligo (Paris, France).
Genomic PCR amplification was performed for 35 cycles with Takara Taq polymerase (Cambrex, Verviers, France) under the following conditions: 30s at 941C for denaturation, 30s at 531C for annealing and 2 min at 721C for extension. 4 cells (in 100 ml) were seeded in triplicate in 96-well flat-bottom microtiter plates. JAK inhibitor I (Merck Biosciences, Bad Soden, Germany) was added as 2 Â concentrated solution in a 100 ml volume. For the last 3 h of the incubation period, 1 mCi [ 3 H]thymidine (Amersham Pharmacia Biotech, Freiburg, Germany) was added to each well. Cells were harvested as described. 17 For cell cycle analysis, cells were fixed with 70% ethanol (À201C, 20 min on ice), washed with phosphate-buffered saline, and stained with propidium iodide (PI) (20 mg/ml). DNA content of the cells was determined by flow cytometry on the FACScan (Becton Dickinson, Heidelberg, Germany). Apoptotic cells were detected and quantitated with the annexin-V/PI method, applying a commercially available kit (R&D Systems, Wiesbaden, Germany). Binding of fluorescein isothiocyanate-labeled annexin-V and PI staining of the cells was determined by flow cytometry.
Results and discussion
Cell lines with JAK2 V617F mutations
It has recently been shown that the majority of patients with PV, and substantial numbers of patients with IM and ET, carry a single nucleotide mutation in the JAK2 gene. [1] [2] [3] [4] [5] [6] The JAK2 V617F mutation was also found in patients with other MPD and the megakaryoblastic variant of AML, although at lower percentages. [6] [7] [8] Since the JAK2 point mutation may contribute to the etiology of these diseases, elucidation of its cellular function(s) may reveal potential therapeutic targets. In numerous cases, the effects of a mutationally altered protein on key cellular functions, including proliferation, differentiation or apoptosis, have been revealed using immortalized cell lines that carry the mutation in question.
To find such a model system for JAK2 V617F in hematopoietic neoplasia, we tested a panel of 42 cell lines derived from patients with MPD, MDS and AML (M7) and compared these with 37 cell lines representing other types of AML (without reportedly antecedant MPD or MDS) and ALL. Cell lines were tested for JAK2 V617F expression applying the PCR-based ARMS system, a method that specifically amplifies the normal and mutant sequences plus a positive control band in a single reaction. 5 According to ARMS and direct sequencing of genomic PCR products, 5/79 cell lines carried the JAK2 V617F mutation (Figure 1a and b) : MB-02 derived from a patient with a history of IM and myeloid metaplasia that developed into AML M7;
14 MUTZ-8 established from a patient with AML M4 25 years after the onset of MDS; 18 SET-2 from a patient at the stage JAK2 V617F mutation in cell lines H Quentmeier et al of leukemic transformation of ET; 19 and UKE-1 from a patient with ET, which transformed into acute leukemia. 20 The AML M6-derived cell line HEL was the only JAK2 V617F positive cell line tested lacking a known patient-history of MPD or MDS. 14 However, like other JAK2mu cell lines found in this study, also this cell line showed cytogenetic rearrangements, which are considered hallmarks of AML/MDS: 21 these included losses of long-arm material from both chromosomes 5 or 7 (5qÀ/7qÀ) affecting cell lines HEL, MB-02, MUTZ-8, and SET-2 (Figure 2a-d) , while cell line UKE1 displayed monosomy for chromosome 7 (data not shown). In the case of cell line HEL, formation of 5qÀ/ 7qÀ may be related to treatment received for preceding Hodgkin lymphoma.
14 Coincident 5qÀ and 7qÀ occur rather rarely in AML, o10% according to Mitelman's database (http:// cgap.nci,nih.gov/Chromosomes/Mitelman), and their presence in 4/5 JAK2mu cell lines is noteworthy, raising the intriguing possibility of their nonrandom association.
Sequencing of JAK2 PCR products suggested that cell line SET-2 expressed the wt and the mutant allele of JAK2, the four other cell lines expressed the mutant allele only (Figure 1b) . These results were confirmed by analyses using the JAK2 wt specific restriction enzyme BsaXI (Figure 1c) .
JAK2 V617F mutations occur often in MPD patients with PV, ET and IM, but not in patients with Philadelphia-positive CML.
1-6 Accordingly, 3/5 cell lines from patients with a history of ET and IM, and 0/17 CML cell lines expressed the JAK2 point mutation.
The JAK2 V617F mutation has been described as an infrequent event in 'atypical MPD', MDS and in megakaryocytic leukemia. [6] [7] [8] We tested 20 cell lines from patients with a history of CNL (n ¼ 1), hypereosinophilic syndrome (n ¼ 1), myeloid metaplasia (n ¼ 1), MDS (n ¼ 8) and AML (M7) (n ¼ 9): of these, JAK2 V617F mutation in cell lines H Quentmeier et al MUTZ-8 was the sole example which expressed the JAK2 mutation.
The JAK2 mutation had not been reported in AML (M1-M6) 5, 6 or ALL. 6, 8 We found no JAK2 V617F in ALL cell lines (0/19), and only in 1/18 AML (M1-M6) cell lines. Cell line HEL alone tested positive for JAK2 V617F of 18 AML (M2-M6) cell lines without a known background of MPD/MDS. However, as pointed out, also this cell line carries chromosomal stigmata of MDS similar to the remaining JAK2 V617F positives described in this study.
In conclusion, the percentages of cell lines carrying the JAK2 V617F mutation reflect the situation in the primary diseases 
Chromosome 9p LOH
About 40% of JAK2 V617F positive MPD patients express the homozygous mutation. 2, 4, 5 We observed that also 4/5 JAK2mu cell lines (80%) show exclusive expression of the mutant variant of the JAK2 gene (Figure 1 ). Microsatellite analysis showed that these cell lines display chromosome 9p21/p22 LOH (Table 1) .
LOH might result from losses of chromosome 9, either wholly (monosomy), or in part (9pÀ), or by mitotic recombination. The current view is that mitotic recombination effects partial chromosome 9 LOH in JAK2mu MPD. 1, 2, 4 However, the combined results of microsatellite (i) and FISH (ii) analyses provide compelling evidence for alternative mechanisms underlying LOH.
Ad (i): none of the four homozygously JAK2mu cell lines display declining heterozygosity at more distant microsatellite markers D9S925 and D9S161, 13 and 22 Mbp centromeric of JAK2 (Table 1) , respectively, contrasting with previous reports invoking mitotic crossing over where heterozygosity rises from 21 to 66% over the same distance. 4 Ad (ii): FISH analysis of JAK2 V617F cell lines with a panel of BAC clones covering almost the entire short-arm of chromosome 9 revealed wide discrepancies in both copy numbers and chromosomal configurations. While MB-02, MUTZ-8 and UKE-1 cells yielded apparently normal diploid signals (Figure 2e and f; Table 2 ), HEL and SET-2 cells displayed patterns consistent with both genomic amplification and deletion (Figure 2g and h) . In the case of SET-2 cells, JAK2 amplification occurred via formation of a series of small marker chromosomes, including an isochromosome which together increased the JAK2 copy number three-fold over diploid levels (Figure 2h) . No normal chromosome 9 homolog was present, replaced by a singleton del(9)(p11p23-24) from which material centromeric of clone 175e13 (8.4 Mbp) was deleted ( Figure 2h ; Table 2 ). Thus, LOH centromeric of JAK2 was directly attributable to a combination of partial 9p deletion and selective JAK2 amplification in SET-2 cells. In triploid HEL cells, similar processes effected B10-fold (diploid-corrected) JAK-2 amplification via an estimated 8-fold tandem duplication, affecting each of a pair of closely related marker chromosomes ( Figure 2g ; Table 2 ). Again no normal homolog was present explaining LOH in this cell line also. Comparison with the distinct DAMI subclone of HEL, isolated at early passage, 22 revealed identical 9p configurations, including JAK2 amplification, consistent with primordial JAK2 rearrangement (data not shown). The five JAK2mu cell lines and two JAK2wt control cell lines chosen at random were analyzed. Shown are the numbers of alleles for six microsatellites on chromosome 9p. Location of microsatellites is indicated in brackets. JAK2 is located at 9p24.1 (5, 011988) , between D9S1810 and D9S1681. D9S925 and D9S161 are, respectively, located 13 and 22 Mbp centromeric of JAK2. Database estimates of heterozygosity (HET) for the microsatellites are given in square brackets. The low HET value may explain D9S1681 homozygosity in the JAK2 wild-type cell line SIG-M5.
Table 2
Copy number and configuration of Chromosome 9p in JAK2 mutant cell lines Microsatellite analysis confirmed that in SET-2 cells, one of the JAK2 loci was amplified: the signal intensity of one allele of the JAK2 adjacent microsatellite D9S1681 was much higher than that of the other (Figure 3 ). JAK2 sequencing and BsaXI digestion experiments confirmed these results and suggested furthermore that it was the mutant variant of JAK2 that was amplified as implied by the cytogenetic findings: in both assays, signal intensities for JAK2mu were distinctly higher than for JAK2wt (Figure 1b and c) .
Thus, results of FISH analysis in cell lines HEL and SET-2 suggest that homozygous expression of JAK2mu may not only be the result of mitotic recombination, but also the consequence of loss and amplification of chromosome 9p21.
Taken together, the cytogenetic and LOH data are not generally explicable by mitotic recombination alone, and instead favor a combination of selective JAK2mu amplification and deletion of the homologous chromosome, either in part, sparing JAK2wt (SET-2), or in entirety (HEL). While the data on remaining cell lines (MB-02, MUTZ-8, UKE-1) are less unequivocal, the absence of any differential LOH along 9p therein provides no positive support for mitotic crossing over, again leaving open the possibility of deletion/duplication.
Inhibition of JAK2
JAK2 protein was expressed in JAK2mu and JAK2wt cell lines likewise (data not shown). It had been reported that JAK inhibitor I downregulated the phosphorylation of JAK2 in the JAK2mu cell line HEL. 2 We show that at least Â 20 lower concentrations of the inhibitor were necessary for growth inhibition in JAK2mu than in JAK2wt cell lines (Figure 4a ). Likewise, apoptosis was induced at lower doses in JAK2mu than in JAK2wt cell lines (Figure 4b ). These data suggest that the JAK2 V617F mutated kinase has an important effect on cell growth and prevention of apoptosis.
Conclusion
To devise targeted, 'intelligent' therapies, the pathobiology of MPD requires elucidation. Although clinically related, MPD are biologically diverse, demanding a wide range of well characterized in vitro models. Hitherto only one model of JAK2 V617F mutation, HEL cells derived from erythroleukemia, has been available. We describe a further four cell lines, MB-02, MUTZ-8, SET-2, UKE-1 -all established from MPD/MDS patients to serve as appropriate models of JAK2 V617F mutation. We have in addition shown that selective JAK2mu amplification combined with whole or partial deletion of the residual homolog may JAK2 V617F mutation in cell lines H Quentmeier et al underly some instances of 9p LOH, accompanying formation of JAK2 V617F.
